X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-evrysdi-royalty-agreement-with-royalty-pharma-for-up-to-1-5-billion-301961677.html
https://www.globenewswire.com//news-release/2023/10/04/2754294/0/en/Majority-of-newborn-babies-with-spinal-muscular-atrophy-SMA-treated-with-Roche-s-Evrysdi-able-to-sit-independently-after-1-year-of-treatment.html
https://www.reuters.com/world/uk/england-rollout-world-first-seven-minute-cancer-treatment-jab-2023-08-29/
https://www.globenewswire.com/en/news-release/2023/07/21/2708937/0/en/CHMP-recommends-Roche-s-Evrysdi-for-babies-under-two-months-old-with-spinal-muscular-atrophy-SMA.html
https://www.prnewswire.com/news-releases/chmp-recommends-evrysdi-for-babies-under-two-months-old-with-spinal-muscular-atrophy-301883026.html
https://www.globenewswire.com/news-release/2023/03/20/2629908/0/en/New-four-year-data-for-Roche-s-Evrysdi-reinforce-long-term-efficacy-and-safety-profile-in-some-of-the-most-severely-affected-people-with-types-2-and-3-spinal-muscular-atrophy-SMA.html
https://www.fiercepharma.com/pharma/roche-touts-evrysdi-win-previously-treated-patients-turning-heat-sma-rivalry-biogen-and
https://www.globenewswire.com/news-release/2022/10/12/2532465/0/en/Positive-new-data-for-Roche-s-Evrysdi-in-largest-trial-ever-undertaken-in-patients-with-previously-treated-spinal-muscular-atrophy-SMA.html
https://www.biopharmadive.com/news/roche-evrysdi-sma-fda-approval-infants-zolgensma/624608/
https://www.globenewswire.com/news-release/2022/03/16/2404033/0/en/New-data-for-Roche-s-Evrysdi-risdiplam-demonstrate-long-term-efficacy-and-safety-in-a-broad-population-of-people-with-spinal-muscular-atrophy-SMA.html
https://www.fiercepharma.com/pharma/roche-aims-to-widen-evrysdi-s-label-courtesy-speedy-fda-review-young-spinal-muscular-atrophy
https://www.pharmatimes.com/news/nice_recommends_risdiplam_for_spinal_muscular_atrophy_1384068
https://pharmaphorum.com/news/nice-reaches-a-deal-with-roche-on-access-to-oral-sma-drug-evrysdi/
https://www.globenewswire.com/news-release/2021/09/24/2302700/0/en/Roche-presents-new-data-at-World-Muscle-Society-WMS-2021-highlighting-new-advances-for-people-living-with-rare-neuromuscular-disorders.html
https://www.europeanpharmaceuticalreview.com/news/163115/babies-with-sma-able-to-swallow-with-evrysdi-treatment/
https://www.biospace.com/article/releases/biogen-plans-to-initiate-phase-3b-study-evaluating-potential-benefit-of-a-higher-dose-of-nusinersen-in-patients-previously-treated-with-evrysdi-risdiplam-/?s=71
https://www.globenewswire.com/news-release/2021/09/15/2297403/0/en/Biogen-Plans-to-Initiate-Phase-3b-Study-Evaluating-Potential-Benefit-of-a-Higher-Dose-of-Nusinersen-in-Patients-Previously-Treated-with-Evrysdi-risdiplam.html
https://www.newswire.ca/news-releases/evrysdi-r-risdiplam-receives-cadth-reimbursement-recommendation-for-some-patients-with-spinal-muscular-atrophy-873584378.html
http://www.pharmafile.com/news/579198/nice-rejects-risdiplam-treating-spinal-muscular-atrophy
https://endpts.com/roche-touts-2-year-efficacy-data-for-sma-therapy-evrysdi-nih-funds-new-network-to-study-flu-and-viruses-with-pandemic-potential/
https://www.biospace.com/article/releases/health-canada-authorizes-evrysdi-and-174-risdiplam-for-the-treatment-of-spinal-muscular-atrophy-sma-in-adults-and-children/
https://www.clinicaltrialsarena.com/news/ptcs-evrysdi-improves-motor-function-and-survival-in-infants-with-sma/
http://www.pharmafile.com/news/576184/roche-s-evrysdi-drug-sma-shown-significantly-increase-survival
https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-commercial-milestone-payment-following-the-recent-european-approval-of-evrysdi-301260436.html
https://www.nasdaq.com/articles/roches-evrysdi-wins-eu-approval-for-spinal-muscular-atrophy-2021-03-30#:~:text=It%20has%20been%20approved%20for,four%20SMN2%20copies%2C%20it%20said.
https://endpts.com/takeda-takes-a-swing-at-rna-small-molecules-with-discovery-pact-for-multiple-potential-evotec-programs/
https://www.prnewswire.com/news-releases/results-from-the-second-year-of-evrysdi-risdiplam-treatment-demonstrated-sustained-improvement-of-motor-function-in-a-broad-range-of-sma-patients-301247815.html
http://www.pharmatimes.com/news/evrysdi_leads_latest_chmp_recommendations_1364324
https://www.raps.org/news-and-articles/news-articles/2021/2/chmps-february-recommendations-evrysdi-jemperli-an
https://www.prnewswire.com/news-releases/positive-data-from-firefish-study-of-evrysdi-risdiplam-in-infants-with-type-1-spinal-muscular-atrophy-published-in-the-new-england-journal-of-medicine-301235049.html
https://www.prnewswire.com/news-releases/evrysdi-risdiplam-continues-to-make-global-progress-for-the-treatment-of-spinal-muscular-atrophy-301156965.html
https://www.fiercepharma.com/marketing/roche-touts-2-year-evrysdi-data-as-oral-sma-drug-drives-early-interest
https://www.fiercepharma.com/marketing/relief-for-biogen-and-roche-novartis-plan-for-zolgensma-older-patients-hits-setback-fda
Market Place
Share 
